ArticleMetabolites2026
A Pilot Serum Metabolomics Reveals Mitochondrial Dysfunction and Identifies Methylguanidine as a Potential Diagnostic Biomarker for ATAAD with Mesenteric Malperfusion Syndrome.
Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute type A aortic dissection complicated by mesenteric malperfusion syndrome (ATAAD-MMPS) is a highly lethal emergency with diagnostic challenges due to rapid progression and non-specific symptoms. This pilot study aimed to characterize the serum metabolomic and lipidomic alterations specific to ATAAD-MMPS and identify potential early diagnostic biomarkers.
methodsSerum samples from healthy controls, patients with uncomplicated ATAAD, and patients with ATAAD-MMPS were analyzed using targeted metabolomics and lipidomics. Multivariate statistical analyses were performed to discriminate between groups and identify differentially abundant metabolites and lipids. Pathway analysis was conducted to explore underlying pathological mechanisms.
resultsMetabolomic profiles clearly distinguished ATAAD-MMPS from uncomplicated ATAAD, whereas lipidomic changes were primarily associated with ATAAD itself rather than the presence of mesenteric malperfusion. Metabolic pathway analysis revealed significant perturbations in the citric acid cycle, suggesting mitochondrial involvement as a potential pathological feature. Notably, methylguanidine was uniquely and markedly elevated in the ATAAD-MMPS group, demonstrating potential diagnostic value in distinguishing this lethal complication from uncomplicated ATAAD in this exploratory cohort (AUC = 0.923).
conclusionsThis pilot study identifies distinct metabolic signatures associated with mesenteric malperfusion in ATAAD, with mitochondrial metabolic perturbations emerging as a potential contributing mechanism. Methylguanidine represents a candidate early diagnostic biomarker for ATAAD-MMPS, warranting validation in larger prospective studies. These findings provide a foundation for improved diagnostic strategies for this devastating condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.